RBR-84nmnm9
Recruiting
Not Applicable
Evaluation of the use of PET/CT with 18F-PSMA as a staging tool and potential predictor for theranostic therapy in patients diagnosed with Adenoid Cystic Carcinoma
Eduardo Nóbrega Pereira Lima0 sitesJuly 31, 2023
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Eduardo Nóbrega Pereira Lima
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age above 18 years. Histological diagnostic confirmation of Neoplasia Adenoid Cystic Carcinoma (ADC). Ability to understand aspects associated with the proposed clinical study and consent to participate.Patients who have performed at least one onventional imaging (computed tomography, magnetic resonance imaging, ultrasonography, and bone scintigraphy) as part of an initial assessment of the extent of neoplastic disease or as part of a recent assessment of ongoing tumor response to CAdC neoplasia.
Exclusion Criteria
- •Clinical condition that contraindicates the use of targeted imaging for staging conventional or exposure to radiopharmaceuticals such as: ongoing pregnancy, breastfeeding or any condition that the attending physician considers a risk for participation in the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
Exploratory Study of Usefulness of 18F-BPA PET/CT in Clinical Staging of Malignanciespatients with malignanciesJPRN-UMIN000008359"Hotta Group" of National Cancer Center Cancer Research and Development Fund120
Active, not recruiting
Phase 1
se of 18F-PSMA-11 PET for detection of lesions in iodine refractory thyroid cancersEUCTR2021-000456-19-BEniversity Hospital Ghent20
Completed
Not Applicable
Clinical utility of [F-18]PSMA-1007 PET/CT (positron emission tomography/computed tomography) in evaluating preoperative staging of prostate cancer before radical prostatectomyKCT0004476Yonsei University Health System, Severance Hospital126
Active, not recruiting
Phase 1
Prospective evaluation of 68Ga-PSMA PET-CT for Recurrence detection of Prostate Cancer and its impact on patient management. The ProsPERo TrialMales 18 years of age or older with histologically-proven prostate adenocarcinoma and biochemical relapse with rising PSA level after initial treatment with radical curative intent, not yet on palliative systemic treatment and considered for further salvage therapyMedDRA version: 19.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10068979Term: Imaging procedureSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]EUCTR2016-000842-79-BEInstitut Jules Bordet75
Completed
Not Applicable
A retrospective study using 18F-FDG-PET/CT for the prediction of immunotherapy-related interstitial lung disease in lung cancer.Advanced or recurrent lung cancerJPRN-UMIN000053550iigata University Medical and Dental Hospital165